Skip to main content

Advertisement

Table 1 Responses and adverse events

From: Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

Study/report Timing of administration of rituximab Response Adverse events
Shimada et al. [3] 1st: 23 cases NA 10 of 23 cases developed infusion reactions; hypoxia was observed in 3 of the 10 cases and Grade 3 severe hypoxia in 1 case
Shimada et al. [3] 2nd: 25 cases NA 4 of 25 cases developed infusion reactions
Ohkubo et al. [23] 1st CR None
Imahashi et al. [15] 1st CR NA
Aoyama et al. [14] 1st NC Grade 3 sick sinus syndrome
Kaku et al. [16] 1st CR None
Okachi et al. [24] 1st: 2 cases CR NA
Wakamatsu et al. [34] 1st CR NA
Shimizu et al. [27] 1st: 5 cases CR NA
Takahashi et al. [31] 1st CR NA
Tanikawa et al. [33] 1st NC NA
Sawa et al. [26] 1st CR NA
Watanabe et al. [35] 1st CR NA
Sakurai et al. [25] 1st CR NA
Takizawa et al. [32] 1st CR NA
Nakano et al. [22] 1st NC NA
Kotake et al. [21] 2nd CR NA
Shinoda et al. [28] 2nd CR NA
Shimada et al. [1] 2nd CR None
Ishizuka et al. [17] 2nd CR NA
Iwagami et al. [18] 2nd CR NA
Kashizaki et al. [19] 2nd CR Unspecified*
Kobayashi et al. [20] 2nd PR NA
Sakurai et al. [25] 2nd CR None
Suzuki et al. [29] 2nd CR NA
Tadokoro et al. [30] 2nd CR NA
Our other case 1st CR Grade 1 fever, chills, hypoxia
Present case 1st NA Death
  1. NA, not applicable; CR, complete response; NC, no change; PR, partial response. *In this case, rituximab administration was attempted during the first course, but an infusion reaction was observed and the rituximab injection was discontinued. However, rituximab was administered according to protocol during the second course.